Dr. Zahoorudin, MBBS, M.D., is a board-certified diplomate of the American Academy of Stem Cell Physicians. He practices in Pakistan and credits Stemtech’s stem cell nutrition science as the key reason he entered regenerative medicine. He began studying the field in 2008, long before it gained wide attention. Stemtech’s early research on the body’s own stem cell processes first attracted him.
In 2008, while in the United Kingdom, Dr. Zahoorudin joined Stemtech’s US and UK teams. He attended scientific seminars across the UK and Europe. The company focused on how the body releases, circulates, migrates, and homes its own stem cells. These ideas sparked his interest in how endogenous stem and progenitor cells help maintain and repair blood vessels, muscle, bone, and other organs.
“It was Stemtech who gave us the required knowledge — the product knowledge and the mechanism behind stem cell migration, production, multiplication, and homing — before my fellowship, before my board certification. Because of Stemtech, I am in the stem cell field today,” said Dr. Zahoorudin. He now runs one of Pakistan’s advanced stem cell practices and works to expand Stemtech stemceutical products in the region.
Charles S. Arnold, Chairman and CEO of Stemtech Corporation, stated that Stemtech forms the cornerstone of Dr. Zahoorudin’s research and ongoing development. John W. Meyer, President and COO, called the physician’s validation extraordinary progress that matches the science the company was built to deliver.
Stemtech Corporation (OTCID: STEK) is a publicly traded wellness company based in Naples, Florida. It specializes in plant-based stemceuticals designed to support the body’s natural regenerative processes. The current entity was founded in April 2018 after acquiring operations from Stemtech International, Inc., which started in 2005. The predecessor appeared four times on the Inc. 5000 Fastest-Growing Companies list between 2010 and 2015. In 2017–2018 the earlier company faced bankruptcy and restructuring. New ownership and leadership took over. In August 2021 Stemtech completed a reverse merger and began trading publicly. Charles S. Arnold serves as Chairman and CEO. John W. Meyer is President and COO. Other directors include Darryl V. Green, Benjamin Kaplan, and John Thatch. Arnold holds a notable ownership stake among insiders.
Stemtech’s main products support three steps of adult stem cell activity: release, circulation, and migration. Key offerings include stemrelease3 (supports natural stem cell release and telomere health), StemFlo Advanced (supports circulation and cellular communication), and MigraStem (supports migration and healthy aging). The line also covers OraStem toothpaste, Cellect One skin care products featuring HOCL and peptide night cream, and StemPets nutritional supplements for dogs and cats launched in 2025. Products use plant-based ingredients such as fucoidan from Undaria pinnatifida and other botanicals. The company sells through Independent Business Partners in a direct-selling model and works with medical practitioners.
Stemtech continues to expand globally while emphasizing accessible nutritional support for the body’s own stem cell activity. Dr. Zahoorudin’s long use of the products since around 2010 and his recent role on the company’s Life Sciences Advisory Board add medical practitioner validation. Statements about the products have not been evaluated by the FDA. The products are not intended to diagnose, treat, cure, or prevent any disease.
There are no reviews yet. Be the first one to write one.
